Section Arrow
ZYME.NASDAQ
- Zymeworks
Quotes are at least 15-min delayed:2025/07/12 10:04 EDT
Regular Hours
Last
 13.34
-0.32 (-2.34%)
Day High 
13.8 
Prev. Close
13.66 
1-M High
13.7 
Volume 
363.28K 
Bid
12.85
Ask
14.01
Day Low
13.29 
Open
13.58 
1-M Low
12.0634 
Market Cap 
1.02B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 12.9 
20-SMA 12.78 
50-SMA 12.29 
52-W High 17.7 
52-W Low 9.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.50/-1.61
Enterprise Value
1.04B
Balance Sheet
Book Value Per Share
4.34
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
76.30M
Operating Revenue Per Share
6.17
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0502-0.0095-15.91%-- 
INKTMiNK Therapeutics Inc64.17+56.44+730.14%-- 
RXRXRecursion Pharmaceuticals5.28-0.435-7.61%-- 
CVMCel-Sci Corp3.53-0.29-7.59%-- 
MISTMilestone Pharmaceuticals1.56-1-39.06%-- 
Quotes are at least 15-min delayed:2025/07/12 10:04 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.